Moens An L, Claeys Marc J, Wuyts Floris L, Goovaerts Inge, Van Hertbruggen Els, Wendelen Luc C, Van Hoof Viviane O, Vrints Christiaan J
Department of Cardiology, University Hospital of Antwerp, Antwerp, Belgium.
Am J Cardiol. 2007 Feb 15;99(4):476-81. doi: 10.1016/j.amjcard.2006.08.057. Epub 2006 Dec 28.
The aim of this study was to test the influence of high-dose folic acid (10 mg/d) on endothelial function in patients referred for coronary intervention after an acute myocardial infarction (AMI) and determine its relation to homocysteine levels. Flow-mediated dilation (FMD) of the brachial artery was performed in 40 patients after AMI (16 with normal homocysteine levels and 24 patients with elevated levels [>11 micromol/L]). Subjects were randomized to receive first folic acid (10 mg/day; group A) or placebo (group B) for 6 weeks in a double-blind crossover trial with a 2-week washout. Plasma folate, total homocysteine and its subtypes (oxidized, reduced, and protein-bound), FMD, and nitroglycerin-mediated dilation were assessed at baseline and at 6 and 14 weeks. In group A, folic acid improved FMD from 3.98 +/- 0.35% to 6.44 +/- 0.56% (p <0.001). This effect persisted after the crossover with placebo (5.42 +/- 0.59, p = 0.13). In group B, placebo did not increase FMD (4.01 +/- 0.34% vs 4.46 +/- 0.38, p = 0.38); however, a significant increase was observed in the second active treatment period (6.49 +/- 0.56%, p = 0.005). In both groups, improved FMD neither correlated with basal levels of homocysteine and its subtypes nor with changes induced during the folate treatment. Nitroglycerin-mediated dilation did not change significantly in either group. Folic acid increased FMD in both normo- and hyperhomocysteinanemic groups (p = 0.006 and p <0.001). In conclusion, 6-week treatment with high-dose folic acid improves endothelial function in post-AMI patients, independent from homocysteine status. Folic acid can be recommended to improve postinfarction endothelial dysfunction in patients with normo- and hyperhomocysteinemia.
本研究的目的是测试高剂量叶酸(10毫克/天)对急性心肌梗死(AMI)后接受冠状动脉介入治疗患者内皮功能的影响,并确定其与同型半胱氨酸水平的关系。对40例AMI后患者(16例同型半胱氨酸水平正常,24例水平升高[>11微摩尔/升])进行肱动脉血流介导的血管舒张功能(FMD)检测。在一项为期6周的双盲交叉试验中,受试者被随机分为先接受叶酸(10毫克/天;A组)或安慰剂(B组)治疗,洗脱期为2周。在基线、6周和14周时评估血浆叶酸、总同型半胱氨酸及其亚型(氧化型、还原型和与蛋白结合型)、FMD和硝酸甘油介导的血管舒张功能。在A组中,叶酸使FMD从3.98±0.35%提高到6.44±0.56%(p<0.001)。与安慰剂交叉后,这种效果仍然存在(5.42±0.59,p=0.13)。在B组中,安慰剂未增加FMD(4.01±0.34%对4.46±0.38,p=0.38);然而,在第二个活性治疗期观察到显著增加(6.49±0.56%,p=0.005)。在两组中,FMD的改善既与同型半胱氨酸及其亚型的基础水平无关,也与叶酸治疗期间引起的变化无关。两组中硝酸甘油介导的血管舒张功能均无显著变化。叶酸在正常同型半胱氨酸血症组和高同型半胱氨酸血症组均增加了FMD(p=0.006和p<0.001)。总之,高剂量叶酸6周治疗可改善AMI后患者的内皮功能,与同型半胱氨酸状态无关。对于正常同型半胱氨酸血症和高同型半胱氨酸血症患者,推荐使用叶酸来改善梗死后内皮功能障碍。